DK1601694T3 - Anvendelser af IL23-antagonister, relaterede reagenser - Google Patents

Anvendelser af IL23-antagonister, relaterede reagenser

Info

Publication number
DK1601694T3
DK1601694T3 DK04718824T DK04718824T DK1601694T3 DK 1601694 T3 DK1601694 T3 DK 1601694T3 DK 04718824 T DK04718824 T DK 04718824T DK 04718824 T DK04718824 T DK 04718824T DK 1601694 T3 DK1601694 T3 DK 1601694T3
Authority
DK
Denmark
Prior art keywords
antagonists
related reagents
methods
reagents
tumors
Prior art date
Application number
DK04718824T
Other languages
Danish (da)
English (en)
Inventor
Terrill K Mcclanahan
Martin Oft
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK1601694T3 publication Critical patent/DK1601694T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK04718824T 2003-03-10 2004-03-09 Anvendelser af IL23-antagonister, relaterede reagenser DK1601694T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45367203P 2003-03-10 2003-03-10
PCT/US2004/007198 WO2004081190A2 (en) 2003-03-10 2004-03-09 Uses of il-23 agonists and antagonists; related reagents

Publications (1)

Publication Number Publication Date
DK1601694T3 true DK1601694T3 (da) 2009-12-14

Family

ID=32990805

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04718824T DK1601694T3 (da) 2003-03-10 2004-03-09 Anvendelser af IL23-antagonister, relaterede reagenser

Country Status (23)

Country Link
US (4) US7282204B2 (ja)
EP (2) EP2108658B1 (ja)
JP (4) JP4605798B2 (ja)
CN (1) CN1759123B (ja)
AT (1) ATE440864T1 (ja)
AU (2) AU2004219625B9 (ja)
BR (1) BRPI0408247A (ja)
CA (1) CA2518262C (ja)
CL (1) CL2004000467A1 (ja)
CY (1) CY1109468T1 (ja)
DE (1) DE602004022781D1 (ja)
DK (1) DK1601694T3 (ja)
ES (1) ES2330220T3 (ja)
HK (1) HK1076477A1 (ja)
MX (1) MXPA05009717A (ja)
NO (1) NO20054630D0 (ja)
NZ (2) NZ541898A (ja)
PL (1) PL1601694T3 (ja)
PT (1) PT1601694E (ja)
SI (1) SI1601694T1 (ja)
TW (2) TWI357336B (ja)
WO (1) WO2004081190A2 (ja)
ZA (1) ZA200506879B (ja)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CN101824088B (zh) * 2002-10-30 2012-05-30 健泰科生物技术公司 Il-17产生的抑制
NZ541898A (en) * 2003-03-10 2008-07-31 Schering Corp Uses of IL-23 antagonists for the manufacture of a medicament for the treatment of tumors
US7247711B2 (en) 2003-05-09 2007-07-24 Centocor, Inc. IL-23p40 specific antibody
NZ548897A (en) * 2004-02-17 2009-07-31 Schering Corp Methods of modulating IL-23 activity; related reagents
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
AU2005220910A1 (en) * 2004-03-05 2005-09-22 Archemix Corp. Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
EP2292758A3 (en) * 2004-12-20 2013-12-25 Merck Sharp & Dohme Corp. Uses of mammalian cytokine; related reagents
US20090142855A1 (en) * 2005-06-30 2009-06-04 Wei Tang Polynucleotides and Polypeptides of the IL-12 Family of Cytokines
ES2710289T3 (es) 2005-06-30 2019-04-24 Janssen Biotech Inc Anticuerpos anti-IL-23, composiciones, procedimientos y usos
AU2012258409B2 (en) * 2005-06-30 2016-01-07 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
AU2006283194B9 (en) * 2005-08-25 2011-02-03 Eli Lilly And Company Anti-IL-23 Antibodies
SG10201402712QA (en) 2005-08-31 2014-08-28 Merck Sharp & Dohme Engineered anti-il-23 antibodies
WO2007027761A2 (en) 2005-09-01 2007-03-08 Schering Corporation Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
RS60616B1 (sr) 2005-12-29 2020-09-30 Janssen Biotech Inc Humana anti-il-23 antitela, kompozicije, postupci i upotrebe
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
EP1882699A1 (en) * 2006-07-27 2008-01-30 Heinfried Radeke Regulation of interleukin-23
TWI426918B (zh) * 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
CA2678863A1 (en) 2007-02-23 2008-08-28 Schering Corporation Engineered anti-il-23p19 antibodies
PL2059534T3 (pl) 2007-02-23 2012-09-28 Merck Sharp & Dohme Przeciwciała Anty-IL-23p19 wytworzone metodą inżynierii genetycznej
KR20100014568A (ko) 2007-02-28 2010-02-10 쉐링 코포레이션 가공된 항-ｉｌ-23ｒ 항체
NZ597915A (en) 2007-02-28 2013-08-30 Merck Sharp & Dohme Combination therapy for treatment of immune disorders
CA2692037A1 (en) * 2007-07-06 2009-01-15 Valorisation Hsj, Societe En Commandite Il-23 receptor antagonists and uses thereof
AR068723A1 (es) * 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
US20100331545A1 (en) 2007-10-24 2010-12-30 Nippon Chemiphar Co., Ltd. Regulator for signaling toll-like receptor, which comprises cathepsin inhibitor as active ingredient
KR20110025649A (ko) 2008-05-05 2011-03-10 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
US20110158992A1 (en) * 2008-08-27 2011-06-30 Schering Corporation Engineered Anti-IL-23R Antibodies
US20110183859A1 (en) * 2008-09-25 2011-07-28 The United States Of America, As Represented By The Secretary, Inflammatory genes and microrna-21 as biomarkers for colon cancer prognosis
DK2350316T3 (da) * 2008-10-20 2014-05-05 Valipharma Fremgangsmåder og anvendelser der involverer genetiske aberrationer af nav3 og aberrerende ekspression af multiple gener
CA2757237A1 (en) * 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
RU2605318C2 (ru) * 2009-05-05 2016-12-20 Новиммун С.А. Анти-il-17f антитела и способы их применения
US20120269765A1 (en) * 2009-07-24 2012-10-25 Garcia K Christopher Cytokine compositions and methods of use thereof
US20110086806A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that Bind IL-23R
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
EP3281954A1 (en) 2010-11-04 2018-02-14 Boehringer Ingelheim International GmbH Anti-il-23 antibodies
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
USRE49026E1 (en) 2011-06-14 2022-04-12 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
EP3326649B1 (en) 2012-05-03 2022-02-09 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
ES2729603T3 (es) 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
JOP20140049B1 (ar) 2013-03-08 2021-08-17 Lilly Co Eli أجسام مضادة ترتبط بـ il-23
US10507241B2 (en) 2014-07-24 2019-12-17 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of IL-23A related diseases
WO2016036918A1 (en) 2014-09-03 2016-03-10 Boehringer Ingelheim International Gmbh Compound targeting il-23a and tnf-alpha and uses thereof
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
JP6871876B2 (ja) * 2015-03-11 2021-05-19 ラッシュ ユニヴァーシティ メディカル センター がんを治療するための組成物と方法
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
AU2019383017A1 (en) 2018-11-20 2021-06-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
CN113874073A (zh) 2019-05-23 2021-12-31 詹森生物科技公司 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
US5856457A (en) 1991-03-29 1999-01-05 Genentech, Inc. Nucleic acids encoding a human IL-8 receptor
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
WO1997003715A1 (en) 1995-07-21 1997-02-06 The General Hospital Corporation Method and apparatus of enhancing the delivery of a pharmaceutical formulation
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6060284A (en) * 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
EP1135415B1 (en) 1998-12-01 2010-08-11 Facet Biotech Corporation Humanized antibodies to gamma-interferon
ATE389019T1 (de) * 1999-09-09 2008-03-15 Schering Corp Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
KR100869621B1 (ko) * 2000-05-10 2008-11-21 쉐링 코포레이션 포유류 수용체 단백질, 관련 시약 및 방법
AU2318202A (en) 2000-10-06 2002-04-15 Immunex Corp Hematopoietin receptors hpr1 and hpr2
AU2002314825A1 (en) * 2001-05-30 2002-12-09 Centocor, Inc. Anti-p40 immunoglobulin derived proteins, compositions, methods and uses
NZ541898A (en) * 2003-03-10 2008-07-31 Schering Corp Uses of IL-23 antagonists for the manufacture of a medicament for the treatment of tumors

Also Published As

Publication number Publication date
AU2004219625B9 (en) 2010-12-23
US8034341B2 (en) 2011-10-11
CA2518262C (en) 2014-05-06
JP2011032275A (ja) 2011-02-17
US20100003251A1 (en) 2010-01-07
AU2004219625A1 (en) 2004-09-23
SI1601694T1 (sl) 2010-01-29
TWI357336B (en) 2012-02-01
US20040223969A1 (en) 2004-11-11
AU2010212372B2 (en) 2012-12-20
EP2108658A1 (en) 2009-10-14
AU2004219625B2 (en) 2010-08-19
TW201141521A (en) 2011-12-01
BRPI0408247A (pt) 2006-03-01
TW200505479A (en) 2005-02-16
CN1759123B (zh) 2011-04-13
CY1109468T1 (el) 2014-08-13
PT1601694E (pt) 2009-12-03
NZ541898A (en) 2008-07-31
PL1601694T3 (pl) 2010-02-26
JP2014005286A (ja) 2014-01-16
NZ567860A (en) 2009-11-27
NO20054630L (no) 2005-10-07
NO20054630D0 (no) 2005-10-07
CA2518262A1 (en) 2004-09-23
TWI439285B (zh) 2014-06-01
JP2006520781A (ja) 2006-09-14
US7282204B2 (en) 2007-10-16
AU2010212372A1 (en) 2010-09-09
WO2004081190A2 (en) 2004-09-23
EP2108658B1 (en) 2016-06-08
JP4605798B2 (ja) 2011-01-05
JP2007197453A (ja) 2007-08-09
CL2004000467A1 (es) 2005-05-06
ES2330220T3 (es) 2009-12-07
HK1076477A1 (en) 2006-01-20
CN1759123A (zh) 2006-04-12
WO2004081190A3 (en) 2005-02-03
EP1601694B1 (en) 2009-08-26
ZA200506879B (en) 2006-05-31
US20120034219A1 (en) 2012-02-09
ATE440864T1 (de) 2009-09-15
MXPA05009717A (es) 2005-10-18
DE602004022781D1 (de) 2009-10-08
US20080057058A1 (en) 2008-03-06
EP1601694A2 (en) 2005-12-07

Similar Documents

Publication Publication Date Title
DK1601694T3 (da) Anvendelser af IL23-antagonister, relaterede reagenser
NO20064193L (no) fremgangsmate for a modulere cytokinaktivitet, beslektede reagenser
CY1108645T1 (el) Θεραπεια και διαγνωση νεοπλασματων χρησιμοποιωντας θυμικη στρωματικη λεμφοποιητινη
BRPI0507794A (pt) métodos de modular a atividade de il-23, reagentes relacionados
BRPI0415361A (pt) antagonistas do receptor muscarìnico de acetilcolina
NO20052496D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
NO20053590D0 (no) Dobbel modusenhet for kortdistanse, hoyrate og langstanse, lavere dataratekommunikasjon.
EA200702278A1 (ru) Антитела, специфичные в отношении tgf-бета 1
DE602005011780D1 (de) Triazinderivate mit carbamatfunktion
SE0301650D0 (sv) Novel compounds
DE60331395D1 (de) CO2 Inkubator
DE112005002412A5 (de) Kommunikationsgerät, Verfahren zum Bereitstellen von Informationen und diesbezügliche Schnittstelle
IS7441A (is) Peptíðdeformýlasatálmar
NL1021524A1 (nl) Menginrichting.
ITMI20031596A1 (it) Guida per coperture mobili
ES1051463Y (es) Plantilla anatomico-ortopedica inyectada.
ITMI20031904A1 (it) Lampada abbronzante.
ITFI20030259A1 (it) Pigmentatore per la colorazione di pellame e similari.
ES1054423Y (es) Plantilla de calzado almohadillada perfeccionada
SE0302219D0 (sv) Händiga tipset
NL1023104A1 (nl) Menginrichting.
DE502004001309D1 (de) Einrichtung zum Empfang von Verkehrsmeldungen
ITPV20020004A1 (it) Dispositivo per miscelare o amalgamare vernici, pitture o simili.
ES1058723Y (es) Plantillas y elementos correctores terapeuticos a base de aceites esenciales.
ES1055164Y (es) Soporte cuelga-bolsos, perfeccionado.